Current concepts on the role of nitric oxide in portal hypertension

World Journal of Gastroenterology

Volumn 19, Issue 11, 2013, Pages 1707-1717

  Hu, Liang Shuo ^a   George, Jacob ^a   Wang, Jian Hua ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Hepatic stellate cell; Liver cirrhosis; Nitric oxide; Portal hypertension

Indexed keywords

4 FLUORO N INDAN 2 YL BENZAMIDE; ANTIHYPERTENSIVE AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; N (G), N (G) DIMETHYLARGININE; NCX 1000; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; O2 VINYL1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE; PROTEIN KINASE B; REACTIVE NITROGEN SPECIES; RHO KINASE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANGIOGENESIS; DRUG DELIVERY SYSTEM; HUMAN; LIVER CIRRHOSIS; NONHUMAN; OXIDATIVE STRESS; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PROTEIN PHOSPHORYLATION; REVIEW; SPLANCHNIC BLOOD FLOW; VASCULAR RESISTANCE;

EID: 84875406320     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i11.1707     Document Type: Review

References (140)

1. Buob S, Johnston AN, Webster CR. Portal hypertension: pathophysiology, diagnosis, and treatment. J Vet Intern Med 2011; 25: 169-186 [PMID: 21382073 DOI: 10.1111/ j.1939-1676.2011.00691.x]
2. Burroughs AK, Thalheimer U. Hepatic venous pressure gradient in 2010: optimal measurement is key. Hepatology 2010; 51: 1894-1896 [PMID: 20512984 DOI: 10.1002/hep.23710]
3. Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding--unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference. Hepatology 2008; 47: 1764-1772 [PMID: 18435460 DOI: 10.1002/hep.22273]
4. Cichoz-Lach H, Celiński K, Słomka M, Kasztelan-Szczerbińska B. Pathophysiology of portal hypertension. J Physiol Pharmacol 2008; 59 Suppl 2: 231-238 [PMID: 18812641]
5. Moneta GL, Taylor DC, Helton WS, Mulholland MW, Strandness DE. Duplex ultrasound measurement of postprandial intestinal blood flow: effect of meal composition. Gastroenterology 1988; 95: 1294-1301 [PMID: 3049214]
6. Albillos A, Bañares R, González M, Catalina MV, Pastor O, Gonzalez R, Ripoll C, Bosch J. The extent of the collateral circulation infuences the postprandial increase in portal pressure in patients with cirrhosis. Gut 2007; 56: 259-264 [PMID: 16837532 DOI: 10.1136/gut.2006.095240]
7. Bellis L, Berzigotti A, Abraldes JG, Moitinho E, García-Pagán JC, Bosch J, Rodés J. Low doses of isosorbide mononi-trate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology 2003; 37: 378-384 [PMID: 12540788 DOI: 10.1053/jhep.2003.50053]
8. Rockey DC. Hepatic fibrosis, stellate cells, and portal hypertension. Clin Liver Dis 2006; 10: 459-479, vii-viii [PMID: 17162223 DOI: 10.1016/j.cld.2006.08.017]
9. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007; 46: 927-934 [PMID: 17391799 DOI: 10.1016/j.jhep.2007.02.006]
10. Laleman W, Van Landeghem L, Van der Elst I, Zeegers M, Fevery J, Nevens F. Nitrofurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology 2007; 132: 709-719 [PMID: 17258737 DOI: 10.1053/j.gastro.2006.12.041]
11. Abraldes JG, Rodríguez-Vilarrupla A, Graupera M, Zafra C, García-Calderó H, García-Pagán JC, Bosch J. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol 2007; 46: 1040-1046 [PMID: 17335931 DOI: 10.1016/j.jhep.2007.01.020]
12. Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, Nevens F, Sauerbruch T, Heller J. Atorvas-tatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007; 46: 242-253 [PMID: 17596891 DOI: 10.1002/hep.21673]
13. Abraldes JG, Albillos A, Bañares R, Turnes J, González R, García-Pagán JC, Bosch J. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009; 136: 1651-1658 [PMID: 19208350 DOI: 10.1053/j.gastro.2009.01.043]
14. Zafra C, Abraldes JG, Turnes J, Berzigotti A, Fernández M, Garca-Pagán JC, Rodés J, Bosch J. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004; 126: 749-755 [PMID: 14988829 DOI: 10.1053/j.gastro.2003.12.007]
15. Dudzinski DM, Igarashi J, Greif D, Michel T. The regulation and pharmacology of endothelial nitric oxide synthase. Annu Rev Pharmacol Toxicol 2006; 46: 235-276 [PMID: 16402905 DOI: 10.1146/annurev.pharmtox.44.101802.121844]
16. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002; 35: 478-491 [PMID: 11826425]
17. Miles AM, Chen Y, Owens MW, Grisham MB. Fluorometric determination of nitric oxide. Methods 1995; 7: 40-47 [DOI: 10.1006/meth.1995.1006]
18. Dudzinski DM, Michel T. Life history of eNOS: partners and pathways. Cardiovasc Res 2007; 75: 247-260 [PMID: 17466957 DOI: 10.1016/j.cardiores.2007.03.023]
19. Minshall RD, Sessa WC, Stan RV, Anderson RG, Malik AB. Caveolin regulation of endothelial function. Am J Physiol Lung Cell Mol Physiol 2003; 285: L1179-L1183 [PMID: 14604847]
20. Shah V, Cao S, Hendrickson H, Yao J, Katusic ZS. Regulation of hepatic eNOS by caveolin and calmodulin after bile duct ligation in rats. Am J Physiol Gastrointest Liver Physiol 2001; 280: G1209-G1216 [PMID: 11352814]
21. Chen PF, Wu KK. Characterization of the roles of the 594-645 region in human endothelial nitric-oxide synthase in regulating calmodulin binding and electron transfer. J Biol Chem 2000; 275: 13155-13163 [PMID: 10777622 DOI: 10.1074/ jbc.275.17.13155]
22. Shah V, Wiest R, Garcia-Cardena G, Cadelina G, Groszmann RJ, Sessa WC. Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. Am J Physiol 1999; 277: G463-G468 [PMID: 10444461]
23. Matei V, Rodríguez-Vilarrupla A, Deulofeu R, Colomer D, Fernández M, Bosch J, Garcia-Pagán JC. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. Hepatology 2006; 44: 44-52 [PMID: 16799985 DOI: 10.1002/hep.21228]
24. Ghafourifar P, Sen CK. Mitochondrial nitric oxide syn-thase. Front Biosci 2007; 12: 1072-1078 [PMID: 17127362 DOI: 10.2741/2127]
25. Dedio J, König P, Wohlfart P, Schroeder C, Kummer W, Müller-Esterl W. NOSIP, a novel modulator of endothelial nitric oxide synthase activity. FASEB J 2001; 15: 79-89 [PMID: 11149895 DOI: 10.1096/fj.00-0078com]
26. Zimmermann K, Opitz N, Dedio J, Renne C, Muller-Esterl W, Oess S. NOSTRIN: a protein modulating nitric oxide release and subcellular distribution of endothelial nitric oxide syn-thase. Proc Natl Acad Sci USA 2002; 99: 17167-17172 [PMID: 12446846 DOI: 10.1073/pnas.252345399]
27. Schilling K, Opitz N, Wiesenthal A, Oess S, Tikkanen R, Müller-Esterl W, Icking A. Translocation of endothelial nitric-oxide synthase involves a ternary complex with caveo-lin-1 and NOSTRIN. Mol Biol Cell 2006; 17: 3870-3880 [PMID: 16807357 DOI: 10.1091/mbc.E05-08-0709]
28. Bauer PM, Fulton D, Boo YC, Sorescu GP, Kemp BE, Jo H, Sessa WC. Compensatory phosphorylation and protein-protein interactions revealed by loss of function and gain of function mutants of multiple serine phosphorylation sites in endothelial nitric-oxide synthase. J Biol Chem 2003; 278: 14841-14849 [PMID: 12591925 DOI: 10.1074/jbc.M211926200]
29. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmod-ulin enough? J Pharmacol Exp Ther 2001; 299: 818-824 [PMID: 11714864]
30. Michell BJ, Chen Zp T, Stapleton D, Katsis F, Power DA, Sim AT, Kemp BE. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem 2001; 276: 17625-17628 [PMID: 11292821 DOI: 10.1074/jbc.C100122200]
31. Chen ZP, Mitchelhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I, Witters LA, Power DA, Ortiz de Montellano PR, Kemp BE. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 1999; 443: 285-289 [PMID: 10025949 DOI: 10.1016/S0014-5793(98)01705-0]
32. Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-depen-dent endothelial nitric oxide synthase activity. Circ Res 2001; 88: E68-E75 [PMID: 11397791 DOI: 10.1161/hh1101.092677]
33. Michell BJ, Harris MB, Chen ZP, Ju H, Venema VJ, Black-stone MA, Huang W, Venema RC, Kemp BE. Identifcation of regulatory sites of phosphorylation of the bovine endothe-lial nitric-oxide synthase at serine 617 and serine 635. J Biol Chem 2002; 277: 42344-42351 [PMID: 12171920 DOI: 10.1074/ jbc.M205144200]
34. Boo YC, Hwang J, Sykes M, Michell BJ, Kemp BE, Lum H, Jo H. Shear stress stimulates phosphorylation of eNOS at Ser(635) by a protein kinase A-dependent mechanism. Am J Physiol Heart Circ Physiol 2002; 283: H1819-H1828 [PMID: 12384459]
35. Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol 2002; 64: 749-774 [PMID: 11826287 DOI: 10.1146/annurev.physi-ol.64.081501.155952]
36. Wei Q, Xia Y. Proteasome inhibition down-regulates endo-thelial nitric-oxide synthase phosphorylation and function. J Biol Chem 2006; 281: 21652-21659 [PMID: 16737962 DOI: 10.1074/jbc.M602105200]
37. Erwin PA, Lin AJ, Golan DE, Michel T. Receptor-regulated dynamic S-nitrosylation of endothelial nitric-oxide syn-thase in vascular endothelial cells. J Biol Chem 2005; 280: 19888-19894 [PMID: 15774480 DOI: 10.1074/jbc.M413058200]
38. Erwin PA, Mitchell DA, Sartoretto J, Marletta MA, Michel T. Subcellular targeting and differential S-nitrosylation of en-dothelial nitric-oxide synthase. J Biol Chem 2006; 281: 151-157 [PMID: 16286475 DOI: 10.1074/jbc.M510421200]
39. MacMicking J, Xie QW, Nathan C. Nitric oxide and macro-phage function. Annu Rev Immunol 1997; 15: 323-350 [PMID: 9143691 DOI: 10.1146/annurev.immunol.15.1.323]
40. Pautz A, Art J, Hahn S, Nowag S, Voss C, Kleinert H. Regulation of the expression of inducible nitric oxide synthase. Nitric Oxide 2010; 23: 75-93 [PMID: 20438856 DOI: 10.1016/ j.niox.2010.04.007]
41. Mankan AK, Lawless MW, Gray SG, Kelleher D, McManus R. NF-kappaB regulation: the nuclear response. J Cell Mol Med 2009; 13: 631-643 [PMID: 19438970 DOI: 10.1111/ j.1582-4934.2009.00632.x]
42. Basak S, Hoffmann A. Crosstalk via the NF-kappaB signaling system. Cytokine Growth Factor Rev 2008; 19: 187-197 [PMID: 18515173 DOI: 10.1016/j.cytogfr.2008.04.005]
43. Esteban FJ, Pedrosa JA, Jiménez A, Fernández AP, Bentura ML, Martínez-Murillo R, Rodrigo J, Peinado MA. Distribution of neuronal nitric oxide synthase in the rat liver. Neurosci Lett 1997; 226: 99-102 [PMID: 9159499 DOI: 10.1016/ S0304-3940(97)00262-0]
44. Billecke SS, Draganov DI, Morishima Y, Murphy PJ, Dun-bar AY, Pratt WB, Osawa Y. The role of hsp90 in heme-dependent activation of apo-neuronal nitric-oxide synthase. J Biol Chem 2004; 279: 30252-30258 [PMID: 15155759 DOI: 10.1074/jbc.M403864200]
45. Song Y, Zweier JL, Xia Y. Heat-shock protein 90 augments neuronal nitric oxide synthase activity by enhancing Ca2+/ calmodulin binding. Biochem J 2001; 355: 357-360 [PMID: 11284722 DOI: 10.1042/0264-6021]
46. Moleda L, Jurzik L, Froh M, Gäbele E, Hellerbrand C, Straub RH, Schölmerich J, Wiest R. Role of HSP-90 for increased nNOS-mediated vasodilation in mesenteric arteries in portal hypertension. World J Gastroenterol 2010; 16: 1837-1844 [PMID: 20397260 DOI: 10.3748/wjg.v16.i15.1837]
47. Bates TE, Loesch A, Burnstock G, Clark JB. Mitochondrial nitric oxide synthase: a ubiquitous regulator of oxidative phosphorylation? Biochem Biophys Res Commun 1996; 218: 40-44 [PMID: 8573169 DOI: 10.1006/bbrc.1996.0008]
48. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998; 28: 926-931 [PMID: 9755227 DOI: 10.1002/ hep.510280405]
49. Petermann H, Vogl S, Schulze E, Dargel R. Chronic liver injury alters basal and stimulated nitric oxide production and 3H-thymidine incorporation in cultured sinusoidal en-dothelial cells from rats. J Hepatol 1999; 31: 284-292 [PMID: 10453942 DOI: 10.1016/S0168-8278(99)80226-8]
50. Shah V, Toruner M, Haddad F, Cadelina G, Papapetro-poulos A, Choo K, Sessa WC, Groszmann RJ. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999; 117: 1222-1228 [PMID: 10535886 DOI: 10.1016/S0016-5085(99)70408-7]
51. Liu S, Premont RT, Kontos CD, Zhu S, Rockey DC. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med 2005; 11: 952-958 [PMID: 16142243 DOI: 10.1038/nm1289]
52. Mohammadi MS, Thabut D, Cazals-Hatem D, Galbois A, Rudler M, Bonnefont-Rousselot D, Moreau R, Lebrec D, Tazi KA. Possible mechanisms involved in the discrepancy of hepatic and aortic endothelial nitric oxide synthases during the development of cirrhosis in rats. Liver Int 2009; 29: 692-700 [PMID: 19040541 DOI: 10.1111/j.1478-3231.2008.01909.x]
53. Matveev S, Uittenbogaard A, van Der Westhuyzen D, Smart EJ. Caveolin-1 negatively regulates SR-BI mediated selective uptake of high-density lipoprotein-derived cholesteryl ester. Eur J Biochem 2001; 268: 5609-5616 [PMID: 11683884 DOI: 10.1046/j.1432-1033.2001.02496.x]
54. Sanyal AJ. Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 46-53 [PMID: 16265100 DOI: 10.1038/ncpgas-thep0084]
55. Cederbaum AI, Lu Y, Wu D. Role of oxidative stress in alcohol-induced liver injury. Arch Toxicol 2009; 83: 519-548 [PMID: 19448996 DOI: 10.1007/s00204-009-0432-0]
56. Bataller R, Brenner DA. Liver fbrosis. J Clin Invest 2005; 115: 209-218 [PMID: 15690074]
57. Ashton AW, Ware JA. Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration. Circ Res 2004; 95: 372-379 [PMID: 15242977 DOI: 10.1161/01.RES.0000138300.41642.15]
58. García-Calderó H, Rodríguez-Vilarrupla A, Gracia-Sancho J, Diví M, Laviña B, Bosch J, García-Pagán JC. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J Hepatol 2011; 54: 660-665 [PMID: 21159403 DOI: 10.1016/ j.jhep.2010.07.034]
59. Gao Y, Yokota R, Tang S, Ashton AW, Ware JA. Reversal of angiogenesis in vitro, induction of apoptosis, and inhibition of AKT phosphorylation in endothelial cells by thrombox-ane A(2). Circ Res 2000; 87: 739-745 [PMID: 11055976 DOI: 10.1161/01.RES.87.9.739]
60. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG. Oxidation of tetrahydro-biopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111: 1201-1209 [PMID: 12697739]
61. Laleman W, Omasta A, Van de Casteele M, Zeegers M, Vander Elst I, Van Landeghem L, Severi T, van Pelt J, Roskams T, Fevery J, Nevens F. A role for asymmetric dimethylar-ginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology 2005; 42: 1382-1390 [PMID: 16317694 DOI: 10.1002/hep.20968]
62. Yang YY, Lee TY, Huang YT, Chan CC, Yeh YC, Lee FY, Lee SD, Lin HC. Asymmetric dimethylarginine (ADMA) determines the improvement of hepatic endothelial dysfunction by vitamin E in cirrhotic rats. Liver Int 2012; 32: 48-57 [PMID: 22098317 DOI: 10.1111/j.1478-3231.2011.02651.x]
63. Matei V, Rodríguez-Vilarrupla A, Deulofeu R, García-Calde-ró H, Fernández M, Bosch J, Garcia-Pagán JC. Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats. J Hepatol 2008; 49: 192-197 [PMID: 18534709 DOI: 10.1016/ j.jhep.2008.04.014]
64. Ferguson JW, Dover AR, Chia S, Cruden NL, Hayes PC, Newby DE. Inducible nitric oxide synthase activity contributes to the regulation of peripheral vascular tone in patients with cirrhosis and ascites. Gut 2006; 55: 542-546 [PMID: 16299035 DOI: 10.1136/gut.2005.076562]
65. Hennenberg M, Biecker E, Trebicka J, Jochem K, Zhou Q, Schmidt M, Jakobs KH, Sauerbruch T, Heller J. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 2006; 130: 838-854 [PMID: 16530523 DOI: 10.1053/ j.gastro.2005.11.029]
66. Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology 1997; 25: 2-5 [PMID: 8985256 DOI: 10.1002/hep.510250102]
67. Anegawa G, Kawanaka H, Yoshida D, Konishi K, Yamaguchi S, Kinjo N, Taketomi A, Hashizume M, Shimokawa H, Maehara Y. Defective endothelial nitric oxide synthase signaling is mediated by rho-kinase activation in rats with secondary biliary cirrhosis. Hepatology 2008; 47: 966-977 [PMID: 18167063 DOI: 10.1002/hep.22089]
68. Fernández-Varo G, Melgar-Lesmes P, Casals G, Pauta M, Arroyo V, Morales-Ruiz M, Ros J, Jiménez W. Inactivation of extrahepatic vascular Akt improves systemic hemodynamics and sodium excretion in cirrhotic rats. J Hepatol 2010; 53: 1041-1048 [PMID: 20800923 DOI: 10.1016/j.jhep.2010.05.031]
69. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, Buerk DG, Huang PL, Jain RK. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 2001; 98: 2604-2609 [PMID: 11226286 DOI: 10.1073/pnas.041359198]
70. Abraldes JG, Iwakiri Y, Loureiro-Silva M, Haq O, Sessa WC, Groszmann RJ. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver Physiol 2006; 290: G980-G987 [PMID: 16603731 DOI: 10.1152/ ajpgi.00336.2005]
71. Tazi KA, Barrière E, Moreau R, Heller J, Sogni P, Pateron D, Poirel O, Lebrec D. Role of shear stress in aortic eNOS up-regulation in rats with biliary cirrhosis. Gastroenterology 2002; 122: 1869-1877 [PMID: 12055594 DOI: 10.1053/ gast.2002.33586]
72. Kajita M, Murata T, Horiguchi K, Iizuka M, Hori M, Ozaki H. iNOS expression in vascular resident macrophages contributes to circulatory dysfunction of splanchnic vascular smooth muscle contractions in portal hypertensive rats. Am J Physiol Heart Circ Physiol 2011; 300: H1021-H1031 [PMID: 21193589 DOI: 10.1152/ajpheart.00563.2009]
73. Moreau R, Barrière E, Tazi KA, Lardeux B, Dargère D, Urbanowicz W, Poirel O, Chauvelot-Moachon L, Guimont MC, Bernuau D, Lebrec D. Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis. Hepatology 2002; 36: 1070-1078 [PMID: 12395316 DOI: 10.1053/jhep.2002.36501]
74. Malyshev E, Tazi KA, Moreau R, Lebrec D. Discrepant effects of inducible nitric oxide synthase modulation on systemic and splanchnic endothelial nitric oxide synthase activity and expression in cirrhotic rats. J Gastroenterol Hepatol 2007; 22: 2195-2201 [PMID: 18031380 DOI: 10.1111/ j.1440-1746.2006.04608.x]
75. Huang HC, Wang SS, Chang CC, Lee FY, Lin HC, Hou MC, Teng TH, Chen YC, Lee SD. Evolution of portal-systemic collateral vasopressin response in endotoxemic portal hypertensive rats. Shock 2009; 32: 503-508 [PMID: 19295490 DOI: 10.1097/SHK.0b013e3181a1bf86]
76. Wiest R, Cadelina G, Milstien S, McCuskey RS, Garcia-Tsao G, Groszmann RJ. Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology 2003; 38: 1508-1515 [PMID: 14647062]
77. Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Gro-szmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104: 1223-1233 [PMID: 10545521 DOI: 10.1172/JCI7458]
78. Sastre E, Balfagón G, Revuelta-López E, Aller MÁ, Nava MP, Arias J, Blanco-Rivero J. Effect of short- and long-term portal hypertension on adrenergic, nitrergic and sensory functioning in rat mesenteric artery. Clin Sci (Lond) 2012; 122: 337-348 [PMID: 21999248 DOI: 10.1042/CS20110303]
79. Jurzik L, Froh M, Straub RH, Schölmerich J, Wiest R. Up-regulation of nNOS and associated increase in nitrergic vasodilation in superior mesenteric arteries in pre-hepatic portal hypertension. J Hepatol 2005; 43: 258-265 [PMID: 15963596 DOI: 10.1016/j.jhep.2005.02.036]
80. Kaneda K, Ekataksin W, Sogawa M, Matsumura A, Cho A, Kawada N. Endothelin-1-induced vasoconstriction causes a signifcant increase in portal pressure of rat liver: localized constrictive effect on the distal segment of preterminal portal venules as revealed by light and electron microscopy and serial reconstruction. Hepatology 1998; 27: 735-747 [PMID: 9500702 DOI: 10.1002/hep.510270315]
81. Zhang JX, Pegoli W, Clemens MG. Endothelin-1 induces direct constriction of hepatic sinusoids. Am J Physiol 1994; 266: G624-G632 [PMID: 8179001]
82. Kawada N, Tran-Thi TA, Klein H, Decker K. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. Eur J Biochem 1993; 213: 815-823 [PMID: 7682947 DOI: 10.1111/ j.1432-1033.1993.tb17824.x]
83. Mittal MK, Gupta TK, Lee FY, Sieber CC, Groszmann RJ. Nitric oxide modulates hepatic vascular tone in normal rat liver. Am J Physiol 1994; 267: G416-G422 [PMID: 7943239]
84. Zhang B, Borderie D, Sogni P, Soubrane O, Hous-sin D, Calmus Y. NO-mediated vasodilation in the rat liver. Role of hepatocytes and liver endothelial cells. J Hepatol 1997; 26: 1348-1355 [PMID: 9210623 DOI: 10.1016/ S0168-8278(97)80471-0]
85. Ming Z, Han C, Lautt WW. Nitric oxide mediates hepatic arterial vascular escape from norepinephrine-induced constriction. Am J Physiol 1999; 277: G1200-G1206 [PMID: 10600817]
86. Loureiro-Silva MR, Cadelina G, Groszmann R. Nitric oxide modulates both pre-sinusoidal and sinusoidal responses to phenylephrine in normal rat liver. Gastroenterology 2001; 120: A9 [DOI: 10.1016/S0016-5085(08)80043-1]
87. Zhang ZQ, Qiu JF, Luo M, Sun YW, Zhao G, Chen W, Liu H, Wu ZY. Liposome-mediated gene transfer of endothelial nitric oxide synthase to cirrhotic rat liver decreases intrahepatic vascular resistance. J Gastroenterol Hepatol 2008; 23: e487-e493 [PMID: 18070013 DOI: 10.1111/j.1440-1746.2007.05244.x]
88. Yu Q, Shao R, Qian HS, George SE, Rockey DC. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest 2000; 105: 741-748 [PMID: 10727442 DOI: 10.1172/JCI7997]
89. Van de Casteele M, Omasta A, Janssens S, Roskams T, Desmet V, Nevens F, Fevery J. In vivo gene transfer of en-dothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats. Gut 2002; 51: 440-445 [PMID: 12171971 DOI: 10.1136/gut.51.3.440]
90. Rockey DC, Chung JJ. Inducible nitric oxide synthase in rat hepatic lipocytes and the effect of nitric oxide on lipocyte contractility. J Clin Invest 1995; 95: 1199-1206 [PMID: 7533786 DOI: 10.1172/JCI117769]
91. Rockey DC, Housset CN, Friedman SL. Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo. J Clin Invest 1993; 92: 1795-1804 [PMID: 8408632 DOI: 10.1172/JCI116769]
92. Perri RE, Langer DA, Chatterjee S, Gibbons SJ, Gadgil J, Cao S, Farrugia G, Shah VH. Defects in cGMP-PKG pathway contribute to impaired NO-dependent responses in hepatic stellate cells upon activation. Am J Physiol Gastrointest Liver Physiol 2006; 290: G535-G542 [PMID: 16269521 DOI: 10.1152/ ajpgi.00297.2005]
93. Failli P, Defranco RM, Caligiuri A, Gentilini A, Romanelli RG, Marra F, Batignani G, Guerra CT, Laff G, Gentilini P, Pinzani M. Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. Gastroenterology 2000; 119: 479-492 [PMID: 10930383]
94. Vorobioff J, Bredfeldt JE, Groszmann RJ. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 1984; 87: 1120-1126 [PMID: 6479534]
95. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994; 20: 1359-1363 [PMID: 7927273 DOI: 10.1002/ hep.1840200538]
96. Yang YY, Huang YT, Lee KC, Lee FY, Lee TY, Hou MC, Lin HC, Lee SD. Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis. Clin Sci (Lond) 2009; 116: 71-79 [PMID: 18479249 DOI: 10.1042/ CS20080075]
97. Leifeld L, Fielenbach M, Dumoulin FL, Speidel N, Sauerbruch T, Spengler U. Inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) expression in fulminant hepatic failure. J Hepatol 2002; 37: 613-619 [PMID: 12399227 DOI: 10.1016/S0168-8278(02)00271-4]
98. Rodríguez-Vilarrupla A, Fernández M, Bosch J, García-Pagán JC. Current concepts on the pathophysiology of portal hypertension. Ann Hepatol 2007; 6: 28-36 [PMID: 17297426]
99. Martin PY, Ginès P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339: 533-541 [PMID: 9709047 DOI: 10.1056/NEJM199808203390807]
100. Thiesson HC, Skøtt O, Jespersen B, Schaffalitzky de Muckadell OB. Nitric oxide synthase inhibition does not improve renal function in cirrhotic patients with ascites. Am J Gastroenterol 2003; 98: 180-186 [PMID: 12526955 DOI: 10.1111/ j.1572-0241.2003.07174.x]
101. Wiest R, Shah V, Sessa WC, Groszmann RJ. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 1999; 276: G1043-G1051 [PMID: 10198349]
102. Theodorakis NG, Wang YN, Wu JM, Maluccio MA, Sitz-mann JV, Skill NJ. Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fbrosis model. Am J Physiol Gas-trointest Liver Physiol 2009; 297: G792-G799 [PMID: 19628654 DOI: 10.1152/ajpgi.00229.2009]
103. Theodorakis NG, Wang YN, Skill NJ, Metz MA, Cahill PA, Redmond EM, Sitzmann JV. The role of nitric oxide synthase isoforms in extrahepatic portal hypertension: studies in gene-knockout mice. Gastroenterology 2003; 124: 1500-1508 [PMID: 12730888 DOI: 10.1016/S0016-5085(03)00280-4]
104. Wei CL, Hon WM, Lee KH, Khoo HE. Chronic administration of aminoguanidine reduces vascular nitric oxide production and attenuates liver damage in bile duct-ligated rats. Liver Int 2005; 25: 647-656 [PMID: 15910502 DOI: 10.1111/ j.1478-3231.2005.01063.x]
105. Bauer TM, Schwacha H, Steinbrückner B, Brinkmann FE, Ditzen AK, Aponte JJ, Pelz K, Berger D, Kist M, Blum HE. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol 2002; 97: 2364-2370 [PMID: 12358257 DOI: 10.1111/ j.1572-0241.2002.05791.x]
106. Guarner C, Soriano G, Tomas A, Bulbena O, Novella MT, Balanzo J, Vilardell F, Mourelle M, Moncada S. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18: 1139-1143 [PMID: 8225220 DOI: 10.1002/hep.1840180520]
107. Albillos A, de la Hera A, González M, Moya JL, Calleja JL, Monserrat J, Ruiz-del-Arbol L, Alvarez-Mon M. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37: 208-217 [PMID: 12500206 DOI: 10.1053/ jhep.2003.50038]
108. Morales-Ruiz M, Jiménez W, Pérez-Sala D, Ros J, Leivas A, Lamas S, Rivera F, Arroyo V. Increased nitric oxide synthase expression in arterial vessels of cirrhotic rats with ascites. Hepatology 1996; 24: 1481-1486 [PMID: 8938184 DOI: 10.1002/ hep.510240630]
109. Bhimani EK, Serracino-Inglott F, Sarela AI, Batten JJ, Mathie RT. Hepatic and mesenteric nitric oxide synthase expression in a rat model of CCl(4)-induced cirrhosis. J Surg Res 2003; 113: 172-178 [PMID: 12943827 DOI: 10.1016/S0022-4804(03)00163-X]
110. Kwon SY, Groszmann RJ, Iwakiri Y. Increased neuronal nitric oxide synthase interaction with soluble guanylate cyclase contributes to the splanchnic arterial vasodilation in portal hypertensive rats. Hepatol Res 2007; 37: 58-67 [PMID: 17300699 DOI: 10.1111/j.1872-034X.2007.00005.x]
111. Lores-Arnaiz S, Perazzo JC, Prestiflippo JP, Lago N, D'Amico G, Czerniczyniec A, Bustamante J, Boveris A, Lemberg A. Hippocampal mitochondrial dysfunction with decreased mtNOS activity in prehepatic portal hypertensive rats. Neu-rochem Int 2005; 47: 362-368 [PMID: 16005112 DOI: 10.1016/ j.neuint.2005.05.006]
112. Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009; 50: 604-620 [PMID: 19157625 DOI: 10.1016/j.jhep.2008.12.011]
113. Bosch J, Abraldes JG, Fernández M, García-Pagán JC. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol 2010; 53: 558-567 [PMID: 20561700 DOI: 10.1016/ j.jhep.2010.03.021]
114. Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 2004; 126: 886-894 [PMID: 14988842 DOI: 10.1053/j.gastro.2003.12.012]
115. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Benefcial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009; 49: 1245-1256 [PMID: 19137587 DOI: 10.1002/hep.22758]
116. Zhao Y, Wang Y, Wang Q, Liu Z, Liu Q, Deng X. Hepatic stellate cells produce vascular endothelial growth factor via phospho-p44/42 mitogen-activated protein kinase/cyclo-oxygenase-2 pathway. Mol Cell Biochem 2012; 359: 217-223 [PMID: 21863308 DOI: 10.1007/s11010-011-1016-x]
117. Medina J, Arroyo AG, Sánchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004; 39: 1185-1195 [PMID: 15122744 DOI: 10.1002/ hep.20193]
118. Sieber CC, Sumanovski LT, Stumm M, van der Kooij M, Battegay E. In vivo angiogenesis in normal and portal hypertensive rats: role of basic fbroblast growth factor and nitric oxide. J Hepatol 2001; 34: 644-650 [PMID: 11434609 DOI: 10.1016/S0168-8278(00)00064-7]
119. Sumanovski LT, Battegay E, Stumm M, van der Kooij M, Sieber CC. Increased angiogenesis in portal hypertensive rats: role of nitric oxide. Hepatology 1999; 29: 1044-1049 [PMID: 10094944 DOI: 10.1002/hep.510290436]
120. Ahmad S, Hewett PW, Wang P, Al-Ani B, Cudmore M, Fujisawa T, Haigh JJ, le Noble F, Wang L, Mukhopadhyay D, Ahmed A. Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ Res 2006; 99: 715-722 [PMID: 16946136 DOI: 10.1161/01.RES.0000243989.46006.b9]
121. Huang HC, Wang SS, Hsin IF, Chang CC, Lee FY, Lin HC, Chuang CL, Lee JY, Hsieh HG, Lee SD. Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats. Hepatology 2012; 56: 248-258 [PMID: 22290687 DOI: 10.1002/hep.25625]
122. Huang HC, Chu CJ, Lee FY, Chang FY, Wang SS, Lin HC, Hou MC, Chan CC, Wu SL, Chen CT, Lee SD. Chronic inhibition of nitric oxide ameliorates splanchnic hyposensitivity to glypressin in a hemorrhage-transfused rat model of portal hypertension. Scand J Gastroenterol 2000; 35: 1308-1313 [PMID: 11199372 DOI: 10.1080/003655200453674]
123. Pizcueta P, Piqué JM, Fernández M, Bosch J, Rodés J, Whittle BJ, Moncada S. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992; 103: 1909-1915 [PMID: 1451984]
124. Forrest EH, Jones AL, Dillon JF, Walker J, Hayes PC. The effect of nitric oxide synthase inhibition on portal pressure and azygos blood flow in patients with cirrhosis. J Hepatol 1995; 23: 254-258 [PMID: 8550988 DOI: 10.1016/0168-8278(95)8046 8-4]
125. González-Abraldes J, García-Pagán JC, Bosch J. Nitric oxide and portal hypertension. Metab Brain Dis 2002; 17: 311-324 [PMID: 12602508]
126. Groszmann RJ. Beta-adrenergic blockers and nitrovasodilators for the treatment of portal hypertension: the good, the bad, the ugly. Gastroenterology 1997; 113: 1794-1797 [PMID: 9352888 DOI: 10.1053/gast.1997.v113.agast971131794]
127. Dudenhoefer AA, Loureiro-Silva MR, Cadelina GW, Gupta T, Groszmann RJ. Bioactivation of nitroglycerin and vaso-motor response to nitric oxide are impaired in cirrhotic rat livers. Hepatology 2002; 36: 381-385 [PMID: 12143046 DOI: 10.1053/jhep.2002.34739]
128. Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol 2003; 38 Suppl 1: S54-S68 [PMID: 12591186 DOI: 10.1016/S0168-8278(02)00430-0]
129. Fiorucci S, Antonelli E, Morelli O, Mencarelli A, Casini A, Mello T, Palazzetti B, Tallet D, del Soldato P, Morelli A. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci USA 2001; 98: 8897-8902 [PMID: 11447266 DOI: 10.1073/ pnas.151136298]
130. Fiorucci S, Antonelli E, Brancaleone V, Sanpaolo L, Orlandi S, Distrutti E, Acuto G, Clerici C, Baldoni M, Del Soldato P, Morelli A. NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. J Hepatol 2003; 39: 932-939 [PMID: 14642608 DOI: 10.1016/S0168-8278(03)00393-3]
131. Loureiro-Silva MR, Cadelina GW, Iwakiri Y, Groszmann RJ. A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. J Hepatol 2003; 39: 940-946 [PMID: 14642609 DOI: 10.1016/j.jhep.2003.09.018]
132. Berzigotti A, Bellot P, De Gottardi A, Garcia-Pagan JC, Gagnon C, Spénard J, Bosch J. NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study. Am J Gastroenterol 2010; 105: 1094-1101 [PMID: 19920806 DOI: 10.1038/ajg.2009.661]
133. Saavedra JE, Billiar TR, Williams DL, Kim YM, Watkins SC, Keefer LK. Targeting nitric oxide (NO) delivery in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor-alpha-induced apoptosis and toxicity in the liver. J Med Chem 1997; 40: 1947-1954 [PMID: 9207935 DOI: 10.1021/jm9701031]
134. Qu W, Liu J, Fuquay R, Saavedra JE, Keefer LK, Waalkes MP. The nitric oxide prodrug, V-PYRRO/NO, mitigates arsenic-induced liver cell toxicity and apoptosis. Cancer Lett 2007; 256: 238-245 [PMID: 17658681 DOI: 10.1016/ j.canlet.2007.06.009]
135. González R, Cruz A, Ferrín G, López-Cillero P, Fernández-Rodríguez R, Briceño J, Gómez MA, Rufán S, Mata Mde L, Martínez-Ruiz A, Marin JJ, Muntané J. Nitric oxide mimics transcriptional and post-translational regulation during α-tocopherol cytoprotection against glycochenodeoxycho-late-induced cell death in hepatocytes. J Hepatol 2011; 55: 133-144 [PMID: 21145864 DOI: 10.1016/j.jhep.2010.10.022]
136. DeLeve LD, Wang X, Kanel GC, Ito Y, Bethea NW, McCuskey MK, Tokes ZA, Tsai J, McCuskey RS. Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome. Hepatology 2003; 38: 900-908 [PMID: 14512877]
137. Moal F, Veal N, Vuillemin E, Barrière E, Wang J, Fizanne L, Oberti F, Douay O, Gallois Y, Bonnefont-Rousselot D, Rousselet MC, Calès P. Hemodynamic and antifbrotic effects of a selective liver nitric oxide donor V-PYRRO/NO in bile duct ligated rats. World J Gastroenterol 2006; 12: 6639-6645 [PMID: 17075977]
138. Edwards C, Feng HQ, Reynolds C, Mao L, Rockey DC. Effect of the nitric oxide donor V-PYRRO/NO on portal pressure and sinusoidal dynamics in normal and cirrhotic mice. Am J Physiol Gastrointest Liver Physiol 2008; 294: G1311-G1317 [PMID: 18356534 DOI: 10.1152/ajpgi.00368.2007]
139. Biecker E, Trebicka J, Kang A, Hennenberg M, Sauerbruch T, Heller J. Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension. Liver Int 2008; 28: 331-338 [PMID: 18290775 DOI: 10.1111/j.1478-3231.2008.01664.x]
140. Das A, Mukherjee P, Singla SK, Guturu P, Frost MC, Mukhopadhyay D, Shah VH, Patra CR. Fabrication and characterization of an inorganic gold and silica nanoparticle mediated drug delivery system for nitric oxide. Nanotechnology 2010; 21: 305102 [PMID: 20610873 DOI: 10.1088/0957-4484/21/30/ 305102]